# Correction: The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

**Authors:** C. Hage, V. Rausch, N. Giese, T. Giese, F. Schönsiegel, S. Labsch, C. Nwaeburu, J. Mattern, J. Gladkich, I. Herr

PMC · DOI: 10.1038/s41419-023-06385-9 · Cell Death & Disease · 2024-01-29

## Full-text entities

- **Genes:** MET (MET proto-oncogene, receptor tyrosine kinase) [NCBI Gene 4233] {aka AUTS9, DA11, DFNB97, HGFR, RCCP2, c-Met}
- **Diseases:** pancreatic cancer (MESH:D010190), Cell Death and Disease (MESH:D009081)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10825190/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC10825190/full.md

---
Source: https://tomesphere.com/paper/PMC10825190